Review



the pet edge+ tool  (MIM Software Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MIM Software Inc the pet edge+ tool
    The Pet Edge+ Tool, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+pet+edge++tool/pet+edge+tool/pm39693740-157-15-21
    Average 90 stars, based on 1 article reviews
    the pet edge+ tool - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy.
    Article Snippet: Two board-certified radiologists with experience in PET/CT imaging used the PET-edge tool of MIM software [37] (MIM Software Inc., Cleveland, OH) to measure the MTVwb and the SUVmaxwb, defined as the total MTV and the maximum SUV respectively of all visible tumors in the whole-body scan as previously described [33].

    Article Title: Computationally efficient collimator-detector response compensation in high energy SPECT using 1D convolutions and rotations.
    Article Snippet: Three lesion ROIs were segmented by a physician on a pre-therapeutical PET image using the PET Edge+ tool of MIM v7.2.1 (MIM Software Inc. USA).

    Article Title: Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors
    Article Snippet: For analyzing TLG and MTV, we used the PET Edge [ , , ] tool on MIM software for PET image analysis (version 7.1.4, MIM Software Inc., Cleveland, OH, USA).

    Article Title: Radiomic signature accurately predicts the risk of metastatic dissemination in late-stage non-small cell lung cancer
    Article Snippet: For each patient, the ROI was contoured by the same experienced nuclear medicine specialist using Medical Image Merge (MIM) 7.0.1 software and the PET EdgeTM tool (both MIM Software Inc., OH, USA).

    Article Title: KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver
    Article Snippet: Sixty CLM were segmented using the PET-edge tool of MIM (MIM Software, Inc., Cleveland, Ohio) and a fixed SUV threshold in Hermes Gold LX (Hermes Medical Solutions, Stockholm, Sweden).

    Article Title: Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response?
    Article Snippet: Background: In the context of a phase II trial of risk-adaptive chemoradiation, we evaluated whether tumor metabolic response could serve as a correlate of treatment sensitivity and toxicity.. Methods: Forty-five patients with AJCCv7 stage IIB-IIIB NSCLC enrolled on the FLARE-RT phase II trial (NCT02773238).. [18F]fluorodeoxyglucose (FDG) PET-CT images were acquired prior to treatment and after 24 Gy during week 3.

    Positron Emission Tomography:

    Article Title: Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
    Article Snippet: The present study analyzed 188 patients with malignant pleural mesothelioma.. Histologic type, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, and total lesion glycolysis value were independent predictors.. We developed a novel prognostic risk classification system.

    Article Title: Intra-individual qualitative and quantitative comparison of [ 68 Ga]Ga-DOTATATE PET/CT and PET/MRI
    Article Snippet: .. Delineation was done separately for PET CT and PET MRI using the PET Edge ® tool in MIM version 7.1.5 (MIM Software Inc., Cleveland, OH, USA). ..

    Magnetic Resonance Imaging:

    Article Title: Intra-individual qualitative and quantitative comparison of [ 68 Ga]Ga-DOTATATE PET/CT and PET/MRI
    Article Snippet: .. Delineation was done separately for PET CT and PET MRI using the PET Edge ® tool in MIM version 7.1.5 (MIM Software Inc., Cleveland, OH, USA). ..



    Similar Products

    the pet edge+ tool  (MIM Software Inc)
    90
    MIM Software Inc the pet edge+ tool
    The Pet Edge+ Tool, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+pet+edge++tool/pet+edge+tool/pm39693740-157-15-21
    Average 90 stars, based on 1 article reviews
    the pet edge+ tool - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pet edge+ tool of mim v7.2.1  (MIM Software Inc)
    90
    MIM Software Inc pet edge+ tool of mim v7.2.1
    Pet Edge+ Tool Of Mim V7.2.1, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+pet+edge++tool/pet+edge+tool/pm39693740-157-19-21
    Average 90 stars, based on 1 article reviews
    pet edge+ tool of mim v7.2.1 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pet edge tool  (MIM Software Inc)
    90
    MIM Software Inc pet edge tool
    Consecutive 18 <t>F-FDG-PET/CT</t> images in a non-small cell lung cancer patient who had a braf mutation and was treated with vemurafenib for almost 6 years. The upper panel on the left demonstrates PET/CT fusion images at the same level from July 2014 (VII-2014) to September 2020 (IX-2020). The lower panel on the left shows the MIP images during the same time period (VII-2014–IX-2020). On the right, the quantitative imaging is tabulated in the same chronological order. <t>SUVmax,</t> <t>TLG,</t> MTV, and tumor dimension values are presented in the beginning, i.e., the three first studies, and a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreases, which can also be seen visually.
    Pet Edge Tool, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+pet+edge++tool/pet+edge+tool/pmc11173296-33-8-24
    Average 90 stars, based on 1 article reviews
    pet edge tool - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    gradient-based tool pet edge  (MIM Software Inc)
    90
    MIM Software Inc gradient-based tool pet edge
    Consecutive 18 <t>F-FDG-PET/CT</t> images in a non-small cell lung cancer patient who had a braf mutation and was treated with vemurafenib for almost 6 years. The upper panel on the left demonstrates PET/CT fusion images at the same level from July 2014 (VII-2014) to September 2020 (IX-2020). The lower panel on the left shows the MIP images during the same time period (VII-2014–IX-2020). On the right, the quantitative imaging is tabulated in the same chronological order. <t>SUVmax,</t> <t>TLG,</t> MTV, and tumor dimension values are presented in the beginning, i.e., the three first studies, and a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreases, which can also be seen visually.
    Gradient Based Tool Pet Edge, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+pet+edge++tool/gradient+based+segmentation+method+pet+edge/pm37244360-84-6-10
    Average 90 stars, based on 1 article reviews
    gradient-based tool pet edge - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pet edge tool of mim encore software  (MIM Software Inc)
    90
    MIM Software Inc pet edge tool of mim encore software
    Consecutive 18 <t>F-FDG-PET/CT</t> images in a non-small cell lung cancer patient who had a braf mutation and was treated with vemurafenib for almost 6 years. The upper panel on the left demonstrates PET/CT fusion images at the same level from July 2014 (VII-2014) to September 2020 (IX-2020). The lower panel on the left shows the MIP images during the same time period (VII-2014–IX-2020). On the right, the quantitative imaging is tabulated in the same chronological order. <t>SUVmax,</t> <t>TLG,</t> MTV, and tumor dimension values are presented in the beginning, i.e., the three first studies, and a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreases, which can also be seen visually.
    Pet Edge Tool Of Mim Encore Software, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+pet+edge++tool/pet+edge+tool/pmc10296350-187-13-24
    Average 90 stars, based on 1 article reviews
    pet edge tool of mim encore software - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    the pet edge™ tool  (MIM Software Inc)
    90
    MIM Software Inc the pet edge™ tool
    Consecutive 18 <t>F-FDG-PET/CT</t> images in a non-small cell lung cancer patient who had a braf mutation and was treated with vemurafenib for almost 6 years. The upper panel on the left demonstrates PET/CT fusion images at the same level from July 2014 (VII-2014) to September 2020 (IX-2020). The lower panel on the left shows the MIP images during the same time period (VII-2014–IX-2020). On the right, the quantitative imaging is tabulated in the same chronological order. <t>SUVmax,</t> <t>TLG,</t> MTV, and tumor dimension values are presented in the beginning, i.e., the three first studies, and a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreases, which can also be seen visually.
    The Pet Edge™ Tool, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+pet+edge++tool/pet+edge+tool/med_rxiv__2023__01__31__23285230-78-23-27
    Average 90 stars, based on 1 article reviews
    the pet edge™ tool - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pet-edge tool of mim software  (MIM Software Inc)
    90
    MIM Software Inc pet-edge tool of mim software
    Consecutive 18 <t>F-FDG-PET/CT</t> images in a non-small cell lung cancer patient who had a braf mutation and was treated with vemurafenib for almost 6 years. The upper panel on the left demonstrates PET/CT fusion images at the same level from July 2014 (VII-2014) to September 2020 (IX-2020). The lower panel on the left shows the MIP images during the same time period (VII-2014–IX-2020). On the right, the quantitative imaging is tabulated in the same chronological order. <t>SUVmax,</t> <t>TLG,</t> MTV, and tumor dimension values are presented in the beginning, i.e., the three first studies, and a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreases, which can also be seen visually.
    Pet Edge Tool Of Mim Software, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+pet+edge++tool/pet+edge+tool/pm35090321-57-13-16
    Average 90 stars, based on 1 article reviews
    pet-edge tool of mim software - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Consecutive 18 F-FDG-PET/CT images in a non-small cell lung cancer patient who had a braf mutation and was treated with vemurafenib for almost 6 years. The upper panel on the left demonstrates PET/CT fusion images at the same level from July 2014 (VII-2014) to September 2020 (IX-2020). The lower panel on the left shows the MIP images during the same time period (VII-2014–IX-2020). On the right, the quantitative imaging is tabulated in the same chronological order. SUVmax, TLG, MTV, and tumor dimension values are presented in the beginning, i.e., the three first studies, and a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreases, which can also be seen visually.

    Journal: Journal of Clinical Medicine

    Article Title: Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors

    doi: 10.3390/jcm13113269

    Figure Lengend Snippet: Consecutive 18 F-FDG-PET/CT images in a non-small cell lung cancer patient who had a braf mutation and was treated with vemurafenib for almost 6 years. The upper panel on the left demonstrates PET/CT fusion images at the same level from July 2014 (VII-2014) to September 2020 (IX-2020). The lower panel on the left shows the MIP images during the same time period (VII-2014–IX-2020). On the right, the quantitative imaging is tabulated in the same chronological order. SUVmax, TLG, MTV, and tumor dimension values are presented in the beginning, i.e., the three first studies, and a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreases, which can also be seen visually.

    Article Snippet: For analyzing TLG and MTV, we used the PET Edge [ , , ] tool on MIM software for PET image analysis (version 7.1.4, MIM Software Inc., Cleveland, OH, USA).

    Techniques: Positron Emission Tomography-Computed Tomography, Mutagenesis, Imaging

    Consecutive 18 F-FDG-PET/CT images in a non-small cell cancer patient who had a ret-mutation and was treated with selpercanitib in 2018. The upper panel on the left demonstrates PET/CT fusion images at the same level from November 2018 (XI-2018) to August 2022 (VIII-2022). The lower panel on the left shows the MIP images during the same time period (XI-2018–VIII-2022). On the right, the quantitative imaging is tabulated in the same chronological order. SUVmax, TLG, MTV, and tumor dimension values are presented at the beginning, i.e., the first three studies, where a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreased, which can also be seen visually. A relapse can be seen visually and in quantitative imaging values, but the patient still experienced a clinical benefit from the treatment.

    Journal: Journal of Clinical Medicine

    Article Title: Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors

    doi: 10.3390/jcm13113269

    Figure Lengend Snippet: Consecutive 18 F-FDG-PET/CT images in a non-small cell cancer patient who had a ret-mutation and was treated with selpercanitib in 2018. The upper panel on the left demonstrates PET/CT fusion images at the same level from November 2018 (XI-2018) to August 2022 (VIII-2022). The lower panel on the left shows the MIP images during the same time period (XI-2018–VIII-2022). On the right, the quantitative imaging is tabulated in the same chronological order. SUVmax, TLG, MTV, and tumor dimension values are presented at the beginning, i.e., the first three studies, where a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreased, which can also be seen visually. A relapse can be seen visually and in quantitative imaging values, but the patient still experienced a clinical benefit from the treatment.

    Article Snippet: For analyzing TLG and MTV, we used the PET Edge [ , , ] tool on MIM software for PET image analysis (version 7.1.4, MIM Software Inc., Cleveland, OH, USA).

    Techniques: Positron Emission Tomography-Computed Tomography, Mutagenesis, Imaging

    [ 18 F]FDG-PET/CT images of a patient who had a small intestine gastrointestinal stromal tumor with a kit mutation and was treated with an investigational kit inhibitor from 2016. The upper panel on the left demonstrates PET/CT fusion images at two levels from June 2016 (VI-2016) to August 2018 (VIII-2018) and the corresponding MIP images during the same time period (VI-2016–VIII-2018). On the right, in the upper panel, the quantitative imaging is tabulated in the same chronological order. SUVmax, TLG, MTV, and tumor dimension values are presented; in this lesion, a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreased, which can also be seen visually. The upper panel on the left demonstrates PET/CT fusion images at two levels from September (IX-2018) to December 2020 (XII-2020) and the corresponding MIP images during the same time period (IX-2018–XII-2020). There was a new lesion which increased in size. The quantitative imaging parameters increased in the last two studies, as seen on the right in the lower panel (adapted with different images for this figure from ).

    Journal: Journal of Clinical Medicine

    Article Title: Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors

    doi: 10.3390/jcm13113269

    Figure Lengend Snippet: [ 18 F]FDG-PET/CT images of a patient who had a small intestine gastrointestinal stromal tumor with a kit mutation and was treated with an investigational kit inhibitor from 2016. The upper panel on the left demonstrates PET/CT fusion images at two levels from June 2016 (VI-2016) to August 2018 (VIII-2018) and the corresponding MIP images during the same time period (VI-2016–VIII-2018). On the right, in the upper panel, the quantitative imaging is tabulated in the same chronological order. SUVmax, TLG, MTV, and tumor dimension values are presented; in this lesion, a response can be seen in SUV, TLG, and MTV values. The actual tumor size decreased, which can also be seen visually. The upper panel on the left demonstrates PET/CT fusion images at two levels from September (IX-2018) to December 2020 (XII-2020) and the corresponding MIP images during the same time period (IX-2018–XII-2020). There was a new lesion which increased in size. The quantitative imaging parameters increased in the last two studies, as seen on the right in the lower panel (adapted with different images for this figure from ).

    Article Snippet: For analyzing TLG and MTV, we used the PET Edge [ , , ] tool on MIM software for PET image analysis (version 7.1.4, MIM Software Inc., Cleveland, OH, USA).

    Techniques: Positron Emission Tomography-Computed Tomography, Mutagenesis, Imaging